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OBJECTIVE — We examined whether metabolic syndrome predicts incident type 2 diabetes
more effectively than impaired fasting glucose (IFG) in a general Japanese population.
RESEARCH DESIGN AND METHODS — A total of 1,935 nondiabetic subjects aged
40–79 years were followed-up prospectively for a mean of 11.8 years.
RESULTS — During the follow-up, 286 subjects developed type 2 diabetes. Compared with
thosewithoutmetabolicsyndrome,themultivariate-adjustedhazardratio(HR)forincidenttype
2 diabetes was signiﬁcantly higher in subjects of both sexes with metabolic syndrome, even after
adjustment for confounding factors, age, family history of diabetes, total cholesterol, alcohol
intake, smoking habits, and regular exercise (men: HR 2.58 [95% CI 1.85–3.59]; women: 3.69
[2.58–5.27]). The multivariate-adjusted HR of metabolic syndrome for type 2 diabetes was
slightly lower in men and similar in women compared with that of IFG. The multivariate-
adjusted HR for type 2 diabetes rose progressively as the number of metabolic syndrome com-
ponents increased in both subjects with and without IFG. In stratiﬁed analysis, the multivariate-
adjusted risk of type 2 diabetes was signiﬁcantly higher in subjects with metabolic syndrome
alone (2.37 [1.45–3.88]) or IFG alone (3.49 [2.57–4.74]) and markedly increased in subjects
with both metabolic syndrome and IFG (6.76 [4.75–9.61]) than in subjects with neither meta-
bolicsyndromenorIFG.Furthermore,themultivariate-adjustedriskfortype2diabeteswasalso
signiﬁcantly higher in subjects with both metabolic syndrome and IFG than in those with either
one alone (both P  0.001).
CONCLUSIONS — Our ﬁndings suggest that metabolic syndrome signiﬁcantly increases
the risk of incident type 2 diabetes, independent of IFG, and is therefore a valuable tool to
identify individuals at high risk of type 2 diabetes.
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M
etabolic syndrome consists of a
clustering of cardiovascular risk
factors,suchascentralobesity,el-
evated blood pressure, glucose intoler-
ance, and dyslipidemia, and individuals
with this condition have an elevated risk
of developing cardiovascular diseases
(1–5) and type 2 diabetes in different eth-
nic populations (1–4,6–11). Thus, the
concept of metabolic syndrome could be
used to reduce the incidence of these dis-
eases worldwide. However, a number of
experts in the ﬁeld of diabetes have ques-
tioned whether the idea of metabolic syn-
drome is useful and valuable (12–14).
Because all of the criteria sets for meta-
bolic syndrome have included the com-
ponent of impaired fasting glucose (IFG),
which is a powerful predictor of type 2
diabetes, detractors have questioned
whether the more complex deﬁnition of
metabolic syndrome is better than a sim-
ple measurement of fasting plasma glu-
cose (FPG). However, reported ﬁndings
concerning this issue are controversial: a
cohort study has shown that the ability of
metabolic syndrome to predict type 2 di-
abetes was superior to that of IFG alone
(3), whereas in other studies, the value of
metabolic syndrome was comparable or
inferior to that of IFG alone (2,6,7). Fur-
thermore, most of these epidemiological
studies were performed in Western pop-
ulations, and this subject has not been as-
sessed sufﬁciently in Asian populations.
The purpose of the present study was
to investigate the association between
metabolic syndrome and the develop-
ment of type 2 diabetes in a prospective
study of a deﬁned Japanese population,
taking into account comprehensive risk
factors. In addition, we compared which
of the two measures, metabolic syndrome
or IFG, better predicted incident type 2
diabetes.
RESEARCH DESIGN AND
METHODS
Study population and follow-up
survey
A population-based prospective study of
cardiovascular disease and its risk factors
has been underway since 1961 in the
town of Hisayama, a suburb of the
Fukuoka metropolitan area on Japan’s
Kyushu Island. In 1988, a screening sur-
vey for the present study was performed
in the town. A detailed description of this
survey was published previously (15). In
brief, of the total of 3,227 residents aged
40–79 years based on the town registry,
2,587 residents (participation rate,
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prehensive assessment. After exclusion of
82 subjects who had already had break-
fast, 10 subjects who were receiving insu-
lin therapy, and 15 subjects who
complained of nausea or general fatigue
during the ingestion of glucose, a total of
2,480 subjects completed a 75-g oral glu-
cose tolerance test. Among these, 297
subjects with diabetes, 52 subjects for
whomtherewasnomeasurementofwaist
circumference, and 2 subjects who died
before the start of follow-up were ex-
cluded, and the remaining 2,129 subjects
(894 men and 1,235 women) were en-
rolled in the baseline examination.
The baseline subjects were fol-
lowed-up prospectively from December
1988 to November 2002 by repeated
health examinations. Of the baseline sub-
jects, 1,935 subjects (793 men and 1,142
women) who underwent reexaminations
were ﬁnally selected for the present study
(follow-up rate, 90.9%; mean follow-up
period,11.8years;meanfrequencyoffol-
low-up examinations, 6.9 times). One
subject who developed overt type 1 dia-
betes clinically during the follow-up pe-
riod was censored at the time.
Clinical evaluation and laboratory
measurements
In the baseline and follow-up examina-
tions, the study subjects underwent an
oral glucose tolerance test between 8:00
and 10:30 A.M. after an overnight fast of at
least12h.Bloodfortheglucoseassaywas
obtained by venipuncture into tubes con-
taining sodium ﬂuoride at fasting and at
2-h postload. Plasma glucose concentra-
tions were determined by the glucose ox-
idase method. According to the American
Diabetes Association criteria in 2003
(16), diabetes was deﬁned as FPG con-
centrations of 7.0 mmol/l and/or 2-h
postloadglucoseconcentrationsof11.1
mmol/l and/or the use of antidiabetes
medication. Total and HDL cholesterol
and triglycerides were determined
enzymatically.
At the baseline examination, waist
circumference was measured by a trained
staff member at the umbilical level with
the subject standing. Blood pressure was
obtained three times using a mercury
sphygmomanometer with the subject in a
sitting position; the average values were
used in the analyses. Each participant
completed a self-administered question-
nairecoveringmedicalhistory,antidiabe-
tes and antihypertension treatments,
alcoholintake,smokinghabits,andphys-
ical activity at the screening. Diabetes in
ﬁrst-orsecond-degreerelativeswastaken
to indicate a family history of diabetes.
Alcohol intake and smoking habits were
classiﬁed as either current use or not.
Subjects engaging in sports at least three
times per week during their leisure time
were deﬁned as the regular-exercise
group.
Deﬁnition of metabolic syndrome
The criteria set for metabolic syndrome
used in this study was deﬁned by the up-
dated 2005 National Cholesterol Educa-
tion Program (NCEP) Adult Treatment
Panel III (ATP III) (17). By this deﬁnition,
metabolic syndrome includes the pres-
ence of at least three of ﬁve factors: ele-
vated FPG (5.6 mmol/l), central obesity
for Asians (waist circumference 90 cm
in men and 80 cm in women), elevated
triglycerides (1.68 mmol/l), reduced
HDL cholesterol (1.03 mmol/l for men
and 1.29 mmol/l for women), and ele-
vated blood pressure (blood pressure
130/85 mmHg and/or current use of
antihypertension agents).
Statistical analysis
The SAS software package (version 8.2;
SAS Institute, Cary, NC) was used to per-
formallstatisticalanalyses.Serumtriglyc-
erides were transformed into logarithms
to improve the skewed distribution. Mul-
tivariate-adjustedhazardratios(HRs)and
their95%CIswereestimatedwiththeuse
of the Cox proportional hazards model.
P  0.05 was considered statistically sig-
niﬁcant in all analyses.
Ethical considerations
This study was conducted with the ap-
provaloftheEthicsCommitteeoftheFac-
ulty of Medicine, Kyushu University, and
written informed consent was obtained
from all participants.
RESULTS— During the follow-up,
286 subjects (145 men and 141 women)
developed type 2 diabetes. The baseline
clinical characteristics of subjects by the
presence or absence of incident type 2 di-
abetes are shown in Table 1. The mean
values of fasting and 2-h postload glu-
cose, waist circumference, triglycerides,
and systolic and diastolic blood pressures
andthefrequenciesofmen,familyhistory
ofdiabetes,elevatedbloodpressure,alco-
hol intake, and smoking habits were
higher in subjects who developed type 2
diabetes than in those who did not de-
velopit,andsubjectswithincidenttype2
diabetes had lower HDL cholesterol and
lower frequency of regular exercise. The
mean values for age and total cholesterol
did not differ between the groups.
Themultivariate-adjustedHRsforthe
developmentoftype2diabetesassociated
with metabolic syndrome and its individ-
ual components were estimated by sex
(Table 2). The multivariate analysis
showed that metabolic syndrome was a
Table 1—Baseline characteristics of subjects by the presence or absence of incident type 2
diabetes, 1988
No developed
diabetes
Developed
diabetes
n 1,649 286
Age (years) 57  10 56  9
Men (%) 39.3 50.7
FPG (mmol/l) 5.4  0.5 5.9  0.6
Two-hour postload glucose (mmol/l) 6.4  1.5 7.5  1.8
Family history of diabetes (%) 6.3 14.0
Waist circumference (cm) 80.8  9.0 85.0  8.7
Total cholesterol (mmol/l) 5.35  1.06 5.39  1.07
HDL cholesterol (mmol/l) 1.32  0.30 1.26  0.30
Triglycerides (mmol/l) 1.09 (0.40–2.98) 1.43 (0.45–4.49)
Systolic blood pressure (mmHg) 130  19 137  19
Diastolic blood pressure (mmHg) 77  11 82  12
Elevated blood pressure (%) 48.8 67.8
Current drinking (%) 28.6 39.2
Current smoking (%) 21.6 31.8
Regular exercise (%) 11.3 6.6
Dataaremeans  SD,%,orgeometricmeans(95%CI)fortriglycerides(becauseoftheskeweddistribution).
Elevated blood pressure was deﬁned as blood pressure 130/85 mmHg and/or current use of antihyper-
tension agents.
Mukai and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 32, NUMBER 12, DECEMBER 2009 2289signiﬁcant risk factor for type 2 diabetes
inmenandwomen,evenafteradjustment
for the following confounding factors:
age, family history of diabetes, total cho-
lesterol, alcohol intake, smoking habits,
and regular exercise (men: multivariate-
adjusted HR, 2.58 [95% CI 1.85–3.59],
P  0.001; women: 3.69 [2.58–5.27],
P  0.001). All components of metabolic
syndrome in both sexes, except for re-
duced HDL cholesterol in men, were sig-
niﬁcantly associated with future type 2
diabetes. Among the individual compo-
nentsofmetabolicsyndrome,IFGwasthe
strongest predictor of incident type 2 di-
abetes in both sexes (men: 3.76 [2.57–
5.52], P  0.001; women: 3.50 [2.45–
5.00],P0.001).Comparedwiththatof
IFG,themultivariate-adjustedHRofmet-
abolicsyndromefordevelopingtype2di-
abetes was slightly lower in men and
similar in women. Furthermore, even
when the cutoff point of waist circumfer-
ence for U.S. individuals was used (102
cm in men and 88 cm in women) in the
metabolicsyndromecriteriainsteadofthe
cutoff point for Asians, the HR of meta-
bolic syndrome for incident type 2 diabe-
tes was substantially unchanged (men:
2.48 [1.76–3.51], P  0.001; women:
3.22 [2.27–4.55], P  0.001).
Because IFG is a strong predictor of
future type 2 diabetes, the associations
between the number of the other meta-
bolic syndrome components and the de-
velopment of type 2 diabetes were
examined among individuals with or
without IFG in men and women together
(Table 3). In subjects with normal FPG
levels, the multivariate-adjusted HRs for
type 2 diabetes rose signiﬁcantly as the
number of metabolic syndrome compo-
nents increased (one component: multiva-
riate-adjusted HR 1.76 [95% CI 0.88–
3.50]; two components: 2.49 [1.22–5.06];
three components: 3.71 [1.72–8.02]; and
four components: 5.90 [2.24–15.53];
Ptrend  0.001). Similar relationships
were also observed in subjects with IFG
(one component: 2.38 [1.30–4.35];
two components: 2.98 [1.62–5.47]; three
components: 4.61 [2.48–8.56]; and four
components: 4.22 [2.01–8.83]; Ptrend 
0.001).
Finally, we examined the combined
as well as separate effects of metabolic
syndromeandIFGonthedevelopmentof
type2diabetes.Inthisanalysis,metabolic
syndrome was deﬁned as the presence of
atleastthreemetabolicsyndromecompo-
nents, not including the component of el-
evatedFPG.AsshownintheFigure1,the
multivariate-adjusted HR for future type
2diabeteswassigniﬁcantlyhigherinsub-
jects with metabolic syndrome alone and
inthosewithIFGalonethaninthosewith
neither metabolic syndrome nor IFG; the
former was slightly lower than the latter,
buttherewasnosigniﬁcantdifferencebe-
tween the two (metabolic syndrome
alone: multivariate-adjusted HR 2.37
[95% CI 1.45–3.88], P  0.001; IFG
alone: 3.49 [2.57–4.74], P  0.001).
Furthermore, the subjects who had both
metabolicsyndromeandIFGhadamark-
edly higher HR for the development of
type 2 diabetes (6.76 [4.75–9.61], P 
0.001). The risk of future type 2 diabetes
was also signiﬁcantly higher in subjects
with both metabolic syndrome and IFG
thaninsubjectswithmetabolicsyndrome
alone (2.82 [1.74–4.57], P  0.001) as
well as in those with IFG alone (1.94
[1.44–2.62], P  0.001).
Table 2—Multivariate-adjusted HRs for the development of type 2 diabetes associated with
metabolic syndrome and its individual components
Population
at risk (n)
No.
events
Multivariate-adjusted
HR (95% CI) P
Men
Updated 2005 NCEP ATP III
() 597 82 1 (referent)
() 196 63 2.58 (1.85–3.59) 0.001
IFG
() 401 35 1 (referent)
() 392 110 3.76 (2.57–5.52) 0.001
Central obesity
() 667 103 1 (referent)
() 126 42 2.28 (1.58–3.29) 0.001
Reduced HDL cholesterol
() 614 108 1 (referent)
() 179 37 1.32 (0.90–1.95) 0.16
Elevated triglycerides
() 579 84 1 (referent)
() 214 61 2.05 (1.46–2.88) 0.001
Elevated blood pressure
() 338 41 1 (referent)
() 455 104 2.17 (1.49–3.17) 0.001
Women
Updated 2005 NCEP APT III
() 723 52 1 (referent)
() 419 89 3.69 (2.58–5.27) 0.001
IFG
() 685 47 1 (referent)
() 457 94 3.50 (2.45–5.00) 0.001
Central obesity
() 496 39 1 (referent)
() 646 102 1.96 (1.35–2.85) 0.001
Reduced HDL cholesterol
() 631 64 1 (referent)
() 511 77 1.55 (1.10–2.18) 0.01
Elevated triglycerides
() 973 105 1 (referent)
() 169 36 2.28 (1.54–3.37) 0.001
Elevated blood pressure
() 598 51 1 (referent)
() 544 90 2.49 (1.74–3.58) 0.001
Data are n or HR (95% CI). IFG, FPG levels of 5.6–6.9 mmol/l; central obesity, waist circumference of 90
cminmenand80cminwomen;reducedHDLcholesterol,HDLcholesterollevelsof1.03mmol/linmen
and 1.29 mmol/l in women; elevated triglycerides, triglyceride levels of 1.68 mmol/l; elevated blood
pressure, blood pressure 130/85 mmHg and/or current use of antihypertension agents. Multivariate
adjustmentwasmadeforage,familyhistoryofdiabetes,totalcholesterol,alcoholintake,smokinghabits,and
regular exercise.
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a 14-year follow-up study of a deﬁned
general Japanese population, we demon-
strated that metabolic syndrome deter-
minedbytheupdated2005NCEPATPIII
criteriawasanindependentriskfactorfor
the development of type 2 diabetes in
bothsexesevenafteradjustmentforcom-
prehensive risk factors. The HR of meta-
bolic syndrome for developing type 2
diabetes was slightly lower in men and
similar in women compared with that of
IFG. When subjects were stratiﬁed by the
presence or absence of IFG, the risk of
future type 2 diabetes rose signiﬁcantly as
the number of metabolic syndrome com-
ponents increased in both FPG level
groups. Furthermore, metabolic syn-
drome that did not include the IFG com-
ponent was also a signiﬁcant risk factor
for developing type 2 diabetes, and the
coexistence of metabolic syndrome and
IFG greatly increased the risk of future
type 2 diabetes. These ﬁndings suggest
that the diagnosis of metabolic syndrome
as well as that of IFG is a valuable tool to
identify individuals at increased risk of
type 2 diabetes.
In Japan, there has been only one
prospectivestudytodatethatfoundasig-
niﬁcant association between metabolic
syndrome determined by the World
Health Organization deﬁnition and inci-
denttype2diabetesamongJapanesemale
workers (18). To our knowledge, the
presentstudyistheﬁrstreporttoindicate
that metabolic syndrome was associated
signiﬁcantly with future type 2 diabetes
for individuals of both sexes in a general
Japanese population. Several epidemio-
logical studies examined the relationship
betweenmetabolicsyndromedetermined
by the updated 2005 NCEP ATP III crite-
ria and incident diabetes (3,4,9–11), and
the risks of incident diabetes associated
with metabolic syndrome have differed
among these investigations. In the Fra-
mingham Offspring Study, subjects with
metabolic syndrome had an 8.6-fold
higher risk of future type 2 diabetes than
those without metabolic syndrome (4).
TheSanAntonioHeartStudy,whichcon-
sisted predominantly of Hispanics, also
showedthatthediabetesriskwas6.9-fold
higher in subjects with metabolic syn-
drome than that in subjects without met-
abolic syndrome (3). A similar increased
risk of diabetes was observed among sub-
jects with metabolic syndrome in an Ital-
Figure 1—Multivariate-adjusted HRs for the development of type 2 diabetes according to the presence or absence of metabolic syndrome and IFG.
Metabolicsyndrome(MetS)wasdeﬁnedasthepresenceofatleastthreemetabolicsyndromecomponentsotherthanthatrelatedtoFPG.Multivariate
adjustment was made for age, sex, family history of diabetes, total cholesterol, alcohol intake, smoking habits, and regular exercise. The centers of
the boxes are placed at the estimates of HRs. Error bars indicate 95% CIs. IFG indicates FPG levels of 5.6–6.9 mmol/l. *P  0.001 vs. IFG () and
MetS (). †P  0.001 vs. IFG () and MetS ().
Table3—Multivariate-adjustedHRsforthedevelopmentoftype2diabetesassociatedwiththe
number of metabolic syndrome components excluding IFG by the presence or absence of IFG
FPG
levels
No. of
metabolic
syndrome
components
excluding IFG
Population at
risk (n)
No.
events
Multivariate-
adjusted HR
(95%CI) Ptrend
Normal 0 285 12 1 (referent)
1 399 26 1.76 (0.88–3.50)
2 236 22 2.49 (1.22–5.06)
3 126 15 3.71 (1.72–8.02)
4 40 7 5.90 (2.24–15.53) 0.001
IFG 0 122 13 1 (referent)
1 278 61 2.38 (1.30–4.35)
2 243 62 2.98 (1.62–5.47)
3 153 51 4.61 (2.48–8.56)
4 53 17 4.22 (2.01–8.83) 0.001
Data are n or HR (95% CI). Multivariate adjustment was made for age, sex, family history of diabetes, total
cholesterol, alcohol intake, smoking habits, and regular exercise. Normal, FPG levels of 5.6 mmol/l; IFG,
FPG levels of 5.6–6.9 mmol/l.
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the other hand, metabolic syndrome in-
creased the risk of diabetes two- to four-
fold in studies of Chinese populations
(9,10). In the present analysis, the risk of
developing type 2 diabetes was nearly
threefold higher in men and fourfold
higher in women with metabolic syn-
drome than in those without it, and these
ﬁgures were much lower than the ﬁgures
in Western populations but comparable
to those of other Asian populations. Fur-
thermore, even when the deﬁnition of
waist circumference for U.S. individuals
was used (102 cm in men and 88 cm
inwomen)inthemetabolicsyndromecri-
teria set, the risk of future type 2 diabetes
amongsubjectswithmetabolicsyndrome
was hardly altered. Taken together, these
ﬁndingssuggestthatmetabolicsyndrome
is less strongly associated with increased
risk of type 2 diabetes in Asian popula-
tions than in Western populations. Al-
though the reason for this difference is
unclear,thediversityofetiologyfortype2
diabetes among races could explain it.
That is, an epidemiological study has
shown that the levels of insulin secretion
and resistance differed among various
ethnicgroupsintheU.S.(19);Asianshad
lower levels of insulin secretion than
other ethnic groups, whereas whites, es-
pecially Hispanics, were more insulin re-
sistant than Asians. In addition, Japanese
diabetic individuals were found to have
lowerBMIlevelsthanwesterndiabeticin-
dividuals (20). Thus, we speculate that
insulin resistance may play a lesser role
than impaired insulin secretion in the de-
velopment of type 2 diabetes among
Asian populations. These ﬁndings may
indicate one reason that the impact of
metabolic syndrome, which has features
of insulin resistance, on the development
of type 2 diabetes is lower in Asian pop-
ulations, including ours, than in Western
populations.
There has been controversy over
whether metabolic syndrome is better
than IFG for detecting subjects at high
risk of type 2 diabetes. The San Antonio
Heart Study revealed that metabolic syn-
drome was a better predictor of diabetes
thanIFG(3),whereasotherepidemiolog-
icalstudiesincludingours(2,6,7)showed
thatmetabolicsyndromewascomparable
or inferior to IFG as a predictor of diabe-
tes.Thisdiscrepancyalsomayresultfrom
the difference in the degree of insulin re-
sistance among the populations, because
the study subjects in the San Antonio
Heart Study were more obese than those
in other studies. Thus, metabolic syn-
drome might be less effective in predict-
ing incident type 2 diabetes in relatively
lean ethnic groups. In our study, how-
ever, the risk of type 2 diabetes rose pro-
gressively as the number of the other
metabolic syndrome components in-
creased, not only in subjects with IFG but
also in those with normal FPG levels.
Moreover, our stratiﬁed analysis indi-
cated that metabolic syndrome deﬁned
without the FPG component was also a
signiﬁcant risk factor for future type 2 di-
abetes in individuals both with and with-
out IFG. These results imply that
metabolic syndrome excluding the FPG
component is also an independent risk
factor for incident type 2 diabetes. On the
other hand, in our study, the coexistence
of metabolic syndrome and IFG appeared
to increase the risk of future type 2 diabe-
tescomparedwitheitheronealone.Other
epidemiological studies have also shown
thattype2diabetespredictionwasgreatly
enhanced by adding information on met-
abolic variables to that of IFG (21–23).
Thus, metabolic syndrome would pro-
vide additional information beyond that
provided by IFG alone in regard to the
development of type 2 diabetes.
In our study, reduced HDL choles-
terol was not a signiﬁcant risk factor for
developing type 2 diabetes in men, al-
though lower HDL cholesterol has often
been shown to be a strong predictor of
diabetes in other epidemiological studies
(2,6,7,9,21–23). The reasons for this dis-
crepancy are not precisely known, but a
higher prevalence of drinking habits in
our men (61%) relative to our women
(9%) may contribute to this phenome-
non.Itisknownthatheavyalcoholintake
augments the risk of diabetes (24),
whereas it increases serum HDL choles-
terol levels (25). These effects of alcohol
intake could weaken the association be-
tween HDL cholesterol levels and the risk
of diabetes.
The strengths of our study include a
longitudinal population-based design, a
long duration of follow-up, a sufﬁcient
number of type 2 diabetes events, a high
follow-up rate, and the use of an oral glu-
cose tolerance test for the diagnosis of di-
abetes. However, two limitations of the
presentstudyshouldbediscussed.Oneis
that the diagnosis of metabolic syndrome
was based on a single measurement of its
componentsatbaseline,aswasthecasein
other epidemiological studies. The risk
factor levels might have changed during
the follow-up because of modiﬁcations in
lifestyle or medication. The other limita-
tionisthatthepresentstudylackedinfor-
mation on antilipidemic drugs, such as
ﬁbrates and nicotinic acid, which could
haveaffectedthemetabolismofHDLcho-
lesterol and triglycerides, although these
medicationswererarelyusedinourcoun-
try by 1988, the time of the baseline.
Theselimitationsmayhaveledtomisclas-
siﬁcation of metabolic syndrome. These
biaseshavethepotentialtounderestimate
the association between metabolic syn-
drome and incident type 2 diabetes, and
thus the true impact of metabolic syn-
drome on the occurrence of type 2 diabe-
tes may be stronger than that shown in
our ﬁndings. For this reason, we believe
thattheselimitationswouldnothavesub-
stantially altered our conclusions.
In summary, the present analysis
clearly demonstrated that metabolic syn-
drome was a signiﬁcant risk factor for de-
velopingtype2diabetesinbothsexesina
general Japanese population. Although
the ability of metabolic syndrome to pre-
dict type 2 diabetes was comparable or
inferior to that of IFG, the effects of met-
abolic syndrome on the development of
type 2 diabetes were independent of IFG.
These ﬁndings suggest that the diagnosis
ofmetabolicsyndromeisusefulandvalu-
able for predicting type 2 diabetes even in
relatively lean Asians. Further studies are
needed to verify these ﬁndings in other
populations.
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